What happens after your last dose of Wegovy

The biggest myth: that effects stop the day you miss a dose

The most common misconception people bring to this topic is that Wegovy works like a light switch, on while you inject, off the moment you don't. It doesn't work that way. Semaglutide accumulates in the body over weeks of weekly dosing, and it clears at a similar pace. The NHS medicines information for semaglutide explains the pharmacokinetic profile: with a half-life of around seven days, the medicine reaches steady state after four to five weeks of treatment, and it leaves the system on a comparable timescale.

In practical terms, this means the week after your last dose, semaglutide is still circulating. By week two, levels are roughly a quarter of what they were at steady state. By weeks four to six, it has substantially cleared. Appetite signals return during this window, gradually, not all at once. Some people find the first fortnight after stopping feels much like being on treatment; others notice hunger creeping back within days. Individual variation is real. If you want a closer look at the timelines involved, our page on how long a dose of semaglutide lasts in your system walks through this in more detail.

One note on timing: if your last pen runs out mid-month, near a bank holiday, or just before you'd normally reorder, that gap can feel longer than expected. Planning a repeat order before the final dose rather than after it is the practical habit that avoids an unintended break. Our frequently asked questions cover what to do if a dose is delayed.

What clinical trials found when treatment stopped

The STEP 1 trial, published in the New England Journal of Medicine, followed participants on 2.4 mg semaglutide weekly for 68 weeks. Average weight reduction was around 15%. The trial's one-year follow-up after stopping (without ongoing lifestyle support) showed a substantial portion of that weight returned. By the end of the follow-up period, about two-thirds of the lost weight had been regained on average.

This isn't a failure of the medicine or the patient. Obesity is a chronic condition with strong biological drivers; GLP-1 medicines manage those drivers while you take them. When the medicine stops, so does that suppression. Prescribers who work with Wegovy regularly discuss this before treatment ends, not as a warning but as a reason to plan: whether that means a structured tapering discussion, a transition to a maintenance approach, or a clinical review of whether stopping is the right move at all.

For context on how dose level affects these timelines, you can read about how long 5mg semaglutide lasts and how long 10mg of semaglutide lasts, since higher maintenance doses have a larger reservoir to clear.

Restarting after a gap: what changes and what to expect

If you restart Wegovy after a break, the dose you left at is not automatically where you return. The general clinical principle is that a gap of four weeks or more means restarting from a lower dose (typically the 0.25 mg starting point) and re-titrating. This is a tolerability precaution, not a punishment. The gastrointestinal effects that many people experienced at the start of treatment can return after a break, and beginning at a high dose again raises that risk considerably.

Your prescriber makes this call based on how long the gap was, your current health picture and your response to treatment previously. A clinical review before restarting is standard practice, which is why reordering after a break isn't as simple as continuing where you left off. The dose schedule for Wegovy and what drives titration decisions are covered in detail separately.

Worth knowing: if you switched providers or have been off treatment for a while, most regulated services will ask for evidence of your previous treatment history before prescribing at anything above the starting dose. That's a patient safety measure, not a bureaucratic hurdle.

Practical questions prescribers actually get asked

Two questions come up repeatedly. The first: is it safe to stop abruptly? Yes, there is no physical withdrawal syndrome from stopping semaglutide. The return of appetite is physiological, not withdrawal in the clinical sense. The second: should you taper the dose before stopping? There is no established tapering protocol in the licensed guidance; stopping from any dose is medically acceptable. Some people and prescribers prefer a structured wind-down for psychological reasons, and that conversation is worth having if it matters to you.

For people thinking about what staying on treatment long-term looks like, or whether the costs make sense over time, the cost context for Wegovy is one part of that picture. For anything clinical (timing, restarting, dose changes) the right conversation is with a prescriber who knows your history.

If you're weighing your options or wondering whether you're still a candidate for treatment after a break, checking your eligibility with our prescribers is the place to start.